Biomarkers and targeted systemic therapies in advanced non-small cell lung cancer.
作者： Mukesh Kumar , Vinicius Ernani , Taofeek K. Owonikoko
DOI: 10.1016/J.MAM.2015.06.009
关键词:
摘要: The last decade has witnessed significant growth in therapeutic options for patients diagnosed with lung cancer. This is due major part to our improved technological ability interrogate the genomics of cancer cells, which enabled development biologically rational anticancer agents. recognition that not a single disease entity dates back many decades histological subclassification malignant neoplasms into subcategories small cell (SCLC) and non-small (NSCLC). While SCLC continues be regarded as histologic category, NSCLC subset undergone additional subcategorizations distinct management algorithms specific molecular subtypes. defining characteristics these subtypes have evolved important tools prognosis predicting likelihood benefit when are treated
sci-hub.se 参考文章(130)
Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework* Clinical Pharmacology & Therapeutics. ,vol. 69, pp. 89- 95 ,(2001) , 10.1067/MCP.2001.113989
June Koo Lee, Heae Surng Park, Dong‐Wan Kim, Kimary Kulig, Tae Min Kim, Se‐Hoon Lee, Yoon‐Kyung Jeon, Doo Hyun Chung, Dae Seog Heo, Woo‐Ho Kim, Yung‐Jue Bang, None, Comparative analyses of overall survival in patients with anaplastic lymphoma kinase‐positive and matched wild‐type advanced nonsmall cell lung cancer Cancer. ,vol. 118, pp. 3579- 3586 ,(2012) , 10.1002/CNCR.26668
Liza C. Villaruz, Mark A. Socinski, Diana E. Cunningham, Simion I. Chiosea, Timothy F. Burns, Jill M. Siegfried, Sanja Dacic, The prognostic and predictive value of KRAS oncogene substitutions in lung adenocarcinoma Cancer. ,vol. 119, pp. 2268- 2274 ,(2013) , 10.1002/CNCR.28039
Stephen L. Graziano, Gary P. Gamble, Nancy B. Newman, Lynn Z. Abbott, Michelle Rooney, Sulagna Mookherjee, Melissa L. Lamb, Leslie J. Kohman, Bernard J. Poiesz, Prognostic Significance of K-ras Codon 12 Mutations in Patients With Resected Stage I and II Non–Small-Cell Lung Cancer Journal of Clinical Oncology. ,vol. 17, pp. 668- 668 ,(1999) , 10.1200/JCO.1999.17.2.668
Daniel B. Costa, Susan T. Schumer, Daniel G. Tenen, Susumu Kobayashi, Differential Responses to Erlotinib in Epidermal Growth Factor Receptor (EGFR)-Mutated Lung Cancers With Acquired Resistance to Gefitinib Carrying the L747S or T790M Secondary Mutations Journal of Clinical Oncology. ,vol. 26, pp. 1182- 1184 ,(2008) , 10.1200/JCO.2007.14.9039
Yoon-La Choi, Maruja E. Lira, Mineui Hong, Ryong Nam Kim, So-Jung Choi, Ji-Young Song, Kinnari Pandy, Derrick L. Mann, Joshua A. Stahl, Heather E. Peckham, Zongli Zheng, Joungho Han, Mao Mao, Jhingook Kim, A novel fusion of TPR and ALK in lung adenocarcinoma. Journal of Thoracic Oncology. ,vol. 9, pp. 563- 566 ,(2014) , 10.1097/JTO.0000000000000093
Fred R. Hirsch, Barbara Helfrich, Wilbur A. Franklin, Marileila Varella-Garcia, Daniel C. Chan, Paul A. Bunn, Preclinical studies of gemcitabine and trastuzumab in breast and lung cancer cell lines. Clinical Breast Cancer. ,vol. 3, pp. 12- 16 ,(2002) , 10.3816/CBC.2002.S.003
Adam S Crystal, Alice T Shaw, Lecia V Sequist, Luc Friboulet, Matthew J Niederst, Elizabeth L Lockerman, Rosa L Frias, Justin F Gainor, Arnaud Amzallag, Patricia Greninger, Dana Lee, Anuj Kalsy, Maria Gomez-Caraballo, Leila Elamine, Emily Howe, Wooyoung Hur, Eugene Lifshits, Hayley E Robinson, Ryohei Katayama, Anthony C Faber, Mark M Awad, Sridhar Ramaswamy, Mari Mino-Kenudson, A John Iafrate, Cyril H Benes, Jeffrey A Engelman, None, Patient-derived models of acquired resistance can identify effective drug combinations for cancer Science. ,vol. 346, pp. 1480- 1486 ,(2014) , 10.1126/SCIENCE.1254721
Eamon M. Berge, Robert C. Doebele, Targeted Therapies in Non-Small Cell Lung Cancer: Emerging Oncogene Targets Following the Success of Epidermal Growth Factor Receptor Seminars in Oncology. ,vol. 41, pp. 110- 125 ,(2014) , 10.1053/J.SEMINONCOL.2013.12.006
Sai-Hong Ignatius Ou, Samuel J. Klempner, Joel R. Greenbowe, Michele Azada, Alexa B. Schrock, Siraj M. Ali, Jeffrey S. Ross, Philip J. Stephens, Vincent A. Miller, Identification of a novel HIP1-ALK fusion variant in Non-Small-Cell Lung Cancer (NSCLC) and discovery of ALK I1171 (I1171N/S) mutations in two ALK-rearranged NSCLC patients with resistance to Alectinib. Journal of Thoracic Oncology. ,vol. 9, pp. 1821- 1825 ,(2014) , 10.1097/JTO.0000000000000368